ClinicalTrials.govpublic full text
Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell Transplant
allogeneic hematopoietic stem cell transplant recipient, myeloproliferative neoplasm, recurrent acute lymphoblastic leukemia, recurrent acute myeloid leukemia, recurrent chronic lymphocytic leukemia, recurrent chronic myelogenous leukemia, bcr-abl1 positive, recurrent hematologic malignancy, recurrent hodgkin lymphoma, recurrent myelodysplastic syndrome, recurrent non-hodgkin lymphoma, recurrent plasma cell myeloma, interventional
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 876044
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.